Stay Updated
For all press requests, please reach out to [email protected].
Press Releases
P4AD Responds to Regeneron MFN Deal and Gene Therapy Approval
WASHINGTON, D.C. — Regeneron is the latest drugmaker to reach a most-favored-nation (MFN) pricing agreement with the Trump administration, part of a broader set of voluntary deals aimed at bringing U.S. drug prices in line with those in other high-income countries. The company was the last of the 17 corporations that received letters in July […]
News and Reports
The Washington Times: Letter to the editor: High medication costs harm Latinos
In “Drug price controls jeopardize Latino patients, workers” (Web, March 31) Carlos Orta argued that efforts to lower drug prices would harm Hispanic communities, and he uses familiar pharmaceutical industry talking points to make his argument. Mr. Orta is right that Hispanic patients face disproportionately high rates of chronic disease, but that makes affordable medications even more […]
News and Reports
POLITICO Weekly Trade: Speaking of Tariffs
“There’s a real risk these tariffs will drive up costs and create more uncertainty for millions of patients already struggling to afford their medications,” Merith Basey, CEO of Patients for Affordable Drugs, said in a statement.
News and Reports
POLITICO Weekly Trade: Speaking of Tariffs
“There’s a real risk these tariffs will drive up costs and create more uncertainty for millions of patients already struggling to afford their medications,” Merith Basey, CEO of Patients for Affordable Drugs, said in a statement.
News and Reports
MM+M: What does pharma think about Trump announcing 100% tariffs?
News and Reports
USA Today: How Trump's 100% drug tariffs could reach consumers pocketbooks
Merith Basey, CEO of Patients for Affordable Drugs, warned that terms of the most favored nation drug pricing deals already announced have “not delivered meaningful savings for the vast majority of American patients.” “What Americans need is structural reform that will be long lasting,” Basey told USA TODAY. “What they don’t need is temporary, voluntary […]
News and Reports
Merith Basey, CEO of Patients for Affordable Drugs, warned in a statement that “while these tariffs aim to pressure pharmaceutical corporations into US manufacturing and most favored nation agreements, the current MFN deals remain opaque and voluntary, and have not delivered meaningful savings for the vast majority of American patients. There’s a real risk these […]
News and Reports
POLITICO Prescription Pulse: Patients for Affordable Drugs has added two people to its board
Patients for Affordable Drugs has added two people to its board: Utibe Essien, internal medicine physician and assistant professor of medicine at UCLA, and Jesse Fuchs-Simon, a Philadelphia-based real estate developer and attorney.